Literature DB >> 28944141

Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013.

Abhinav Agrawal1, Abhishek Agarwal2, Dhruv Mehta3, Rutuja R Sikachi1,4, Doantrang Du5, Janice Wang1,6.   

Abstract

Cystic fibrosis (CF) is a multisystem autosomal recessive genetic disorder with significant advances in early diagnosis and treatment in the last decade. It is important to provide updated information regarding these changing demographics as they also reflect a considerable improvement in survival. We analyzed the National Inpatient Sample Database (NIS) in the United States for all patients in which CF was the primary discharge diagnosis (ICD-9: 277.0-277.09) from 2003 to 2013 to evaluate the rate of hospitalizations and determine the cost and mortality associated with CF along with other epidemiological findings. The statistical significance of the difference in the number of hospital discharges, lengths of stays and associated hospital costs over the study period was calculated. In 2003, there were 8,328 hospital discharges with the principal discharge diagnosis of CF in the United States, which increased to 12,590 discharges in 2013 (p < 0.001). The mean hospital charges increased by 57.64% from US$ 60,051 in 2003 to US$ 94,664 in 2013. The aggregate cost of hospital visits increased by 138.31% from US$ 500,105,727 to US$ 1,191,819,760. In the same time, the mortality decreased by 49.3 %. The number of inpatient discharges related to CF has increased from 2003 to 2013. This is due to increased life expectancy of CF patients, resulting in increased disease prevalence. There has been a significant increase in the mean and aggregate cost associated with CF admissions. Over the last decade, many advances have been made in the diagnosis and treatment of CF, consequentially leading to a significant transformation in the epidemiology and demographics of this chronic disease. Rising hospital costs associated with the care of CF patients necessitates future studies analyzing the diagnostic modalities, algorithms and treatment practices of physician's treating CF patients.

Entities:  

Keywords:  Cystic Fibrosis; epidemiology; healthcare burden; hospitalizations; length of stay; mortality

Year:  2017        PMID: 28944141      PMCID: PMC5608929          DOI: 10.5582/irdr.2017.01043

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  19 in total

Review 1.  An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis.

Authors:  R Buzzetti; D Salvatore; E Baldo; M P Forneris; V Lucidi; D Manunza; I Marinelli; B Messore; A S Neri; V Raia; M L Furnari; G Mastella
Journal:  J Cyst Fibros       Date:  2009-05-06       Impact factor: 5.482

2.  Improving the care of infants identified through Cystic Fibrosis newborn screening.

Authors:  Bruce C Marshall; Preston W Campbell
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

3.  Gender gap in cystic fibrosis mortality.

Authors:  M Rosenfeld; R Davis; S FitzSimmons; M Pepe; B Ramsey
Journal:  Am J Epidemiol       Date:  1997-05-01       Impact factor: 4.897

4.  Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis.

Authors:  J R Curtis; W Burke; A W Kassner; M L Aitken
Journal:  Am J Respir Crit Care Med       Date:  1997-06       Impact factor: 21.405

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

Authors:  Kaïssa de Boer; Katherine L Vandemheen; Elizabeth Tullis; Steve Doucette; Dean Fergusson; Andreas Freitag; Nigel Paterson; Mary Jackson; M Diane Lougheed; Vijay Kumar; Shawn D Aaron
Journal:  Thorax       Date:  2011-06-15       Impact factor: 9.139

Review 7.  Epidemiology of Cystic Fibrosis.

Authors:  Kimberly A Spoonhower; Pamela B Davis
Journal:  Clin Chest Med       Date:  2016-03       Impact factor: 2.878

8.  Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.

Authors:  Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

9.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

Review 10.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.

Authors:  Virginia A Stallings; Lori J Stark; Karen A Robinson; Andrew P Feranchak; Hebe Quinton
Journal:  J Am Diet Assoc       Date:  2008-05
View more
  7 in total

1.  Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif).

Authors:  Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock
Journal:  Anal Chim Acta       Date:  2019-01-09       Impact factor: 6.558

2.  Cystic fibrosis patients at risk for disease progression marked by decline in FEV1% predicted: development of the cystic fibrosis risk of disease progression score.

Authors:  Nathan L Marsteller; Eliezer Nussbaum; Tricia Morphew; Inderpal S Randhawa
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Assessing Practices, Beliefs, and Attitudes about Palliative Care among People with Cystic Fibrosis, Their Caregivers, and Clinicians: Results of a Content Analysis.

Authors:  Melissa Basile; Lincy Jojan; Mara R Hobler; Elisabeth P Dellon; Anna M Georgiopoulos; Jessica L Goggin; Elaine Chen; Christopher H Goss; Sarah E Hempstead; Albert Faro; Dio Kavalieratos
Journal:  J Palliat Med       Date:  2021-04-20       Impact factor: 2.947

4.  Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study.

Authors:  Meghana Sathe; Rong Huang; Sonya Heltshe; Alexander Eng; Elhanan Borenstein; Samuel I Miller; Lucas Hoffman; Daniel Gelfond; Daniel H Leung; Drucy Borowitz; Bonnie Ramsey; A Jay Freeman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-09-01       Impact factor: 3.288

5.  Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.

Authors:  Michael M Maiden; Alessandra M Agostinho Hunt; Mitchell P Zachos; Jacob A Gibson; Martin E Hurwitz; Martha H Mulks; Christopher M Waters
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.938

6.  Optimizing Clinical and Cost Outcomes for Patients on Enteral Nutrition Support for Treatment of Exocrine Pancreatic Insufficiency: Proceedings from an Expert Advisory Board Meeting.

Authors:  Joseph I Boullata; Janice L Clarke; Archie Stone; Alexis Skoufalos; David B Nash
Journal:  Popul Health Manag       Date:  2019-06       Impact factor: 2.459

Review 7.  Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases.

Authors:  Ning Shi; Zhihong Wang; Hecheng Zhu; Weidong Liu; Ming Zhao; Xingjun Jiang; Jin Zhao; Caiping Ren; Yan Zhang; Longlong Luo
Journal:  Immunol Res       Date:  2022-02-11       Impact factor: 4.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.